Hyoscine-N-Butyl Bromide can not only be used as a pain management technique, but the market is expected to bring in more than $50 million (~€44.22 million) in 2019.
A new study states that as a pain management technique, the oral consumption of Hyoscine-N-butyl Bromide has increased with a rise in the instances of abdominal cramps and pain, particularly among the adult population.
The study highlights that growing prevalence of irritable bowel syndrome (IBS) will continue to underpin Hyoscine-N-butyl bromide sales. Over the past few years, the prevalence of IBS and abdominal pain as the gastrointestinal tract disorder has increased, resulting in the increasing consumption of anti-spasmodic drugs. IBS has emerged as one of the most common causes of abdominal pain in the last few years, according to the International Foundation for Gastrointestinal Disorders, the prevalence of IBS is estimated around 10-15% globally.
Hyoscine-N-Butyl Bromide and pain management
Alongside Hyoscine-N-Butyl Bromide, the demand for buscopan – a medicine containing Hyoscine-N-butyl bromide – as an active ingredient has witnessed an uptick in the treatment of pain and cramps. Buscopan when orally administered, does not cross the blood brain barrier and has minimal systemic absorption, which in turn complements preference for oral consumption of Hyoscine-N-butyl bromide.
The study opines that growing requirement for on-demand Hyoscine-N-butyl bromide for treatment of self-reported functional abdominal pain and cramping has further been driving the demand for oral mode of delivery of Hyoscine-N-butyl bromide.
On the other hand, in the parasympathetic nervous system, hyoscine N-butyl bromide blocks the transmission of nerve impulses by acetylcholine, which is useful in treatment of spasms in urogenital and gastrointestinal tract. This is driving the sugar-coated tablets consumption that contains 10 mg of the hyoscine N-butyl bromide as an active ingredient.
Europe to remain most lucrative for Hyoscine N-Butyl Bromide market
According to the report, Europe is likely to remain the most lucrative region in the hyoscine N-butyl bromide market, owing to the significant growth in the geriatric population in the region that is more prone to abdominal pain and chronic gastrointestinal diseases.
In Europe, Hyoscine-N-butyl bromide with brand name as buscopan is finding widespread application in the radiology as anti-spasmodic agent. It is also used to freeze the bowel motion as part of MRI and CT studies.
In the past few years, abdominal pain has gained significance as one of the early signs of meningococcal infection in Europe. This form of infection is becoming increasingly common in Europe, with abdominal pain as one of the key symptoms. According to the latest research study, 10% of patients infected with the meningococcal strain in Europe suffer from stomach pain.
More studies required for a better pain management technique
In recent years, acute abdominal pain has been a common complaint among paediatric patients visiting the Emergency Department. Although Hyoscine-N-Butyl Bromide is used widely for abdominal pain in children, no paediatric clinical trial still has explored its efficacy to treat abdominal pain in children in the ED setting.
According to some experts, if Hyoscine-N-Butyl Bromide is found to be an effective drug or medication to treat children suffering from acute abdominal pain, it may emerge as a therapeutic option for the painful condition and for acute abdominal pain in children for which there is currently limited options available.
